Navigation Links
CV Therapeutics Statement on Unsolicited Proposal From Astellas
Date:1/27/2009

PALO ALTO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- In light of an announcement made recently by Astellas Pharma Inc., CV Therapeutics, Inc. (Nasdaq: CVTX) confirmed that it had received a letter dated November 13, 2008 from Astellas setting forth an unsolicited proposal by Astellas to acquire CV Therapeutics at a price of $16.00 per share, subject to due diligence, Astellas board approval and other conditions.

After careful deliberation, with the assistance of its financial and legal advisors, the CV Therapeutics board of directors had, on November 21, 2008, concluded that the Astellas proposal was not in the best interests of CV Therapeutics and its stockholders. Dr. Louis Lange, chairman and chief executive officer of CV Therapeutics, sent a letter dated November 21, 2008 to that effect to Astellas on behalf of the board of directors of CV Therapeutics.

Because Astellas, by its recent announcement, has sought to revive its previously rejected proposal, the CV Therapeutics board of directors will again review developments in the context of the company's strategic plans and the long-term interests of its stockholders, to pursue the best course of action to maximize long-term value for stockholders. As part of its ongoing review of the current market environment and the recent developments relating to CV Therapeutics, the board of CV Therapeutics concluded that it was in the best interests of CV Therapeutics and its stockholders to extend the expiration date of its shareholder rights plan from February 1, 2009 to February 1, 2010. CV Therapeutics will keep its stockholders advised.

Barclays Capital is serving as financial advisor, and Latham & Watkins LLP is serving as legal counsel, to CV Therapeutics.

About CV Therapeutics

CV Therapeutics, Inc., headquartered
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... The discovery 30 years ago of soccer-ball-shaped carbon molecules ... research. Now, there appears to be a new ball ... University and Tsinghua University in China have shown that ... molecular cage similar to a carbon buckyball. It,s the ... a matter of speculationdoes indeed exist. , "This is ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "International Transfection Technology Market - Global Industry Analysis, ... report to their offering. ... to introduce nucleic acids (either DNA or RNA) into ... therapy, mutation of cancer cells and protein metabolism by ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Cayenne ... company specializing in the soft tissue reconstruction segment, ... Anchor System for surgeries involving the shoulder and ... through a novel, inserter-controlled deployment method. The unique ... partial deployment, anchor pull-out, or anchor displacement (also ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
Breaking Biology Technology:Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 3International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... Madison, Wis. - CDW Corp. , a $6 ... Hills, Ill., has agreed to acquire the stock of Madison-based ... cash. , ,The acquisition, which has been approved by ... the end of October, subject to regulatory approvals and approval ...
... Madison, Wis. - Not everyone is a fan ... most up-to-date technology - fiber to the premises. , ... the pack with trailing-edge technology is pervasive, but ... a different calculation. , ,TDS has introduced its Symmetrical ...
... Stem Cell Bank has announced it will receive human ... , giving it 13 of the 21 stem cell lines ... of the WiCell Research Institute , which houses the ... eventually will have all 21 federally approved lines. , ,"We're ...
Cached Biology Technology:Berbee believes acquisition by CDW will make it a national IT player 2Berbee believes acquisition by CDW will make it a national IT player 3TDS believes faster DSL service will suit small businesses 2Nation's only stem cell bank will receive UC-San Francisco cell line 2
(Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
(Date:7/11/2014)... type 1 can inhibit voltage-gated calcium channel, ... release. However, some scholars demonstrated that cannabinoid ... influx and increase neurotransmitter release. Dr. Yi ... to Tongji Medical College, Huazhong University of ... voltage-clamp and calcium imaging in cultured trigeminal ...
(Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... a human hair to deliver drugs to cells or assist ... of a science fiction movie, but these scenarios may be ... Carbon nanotubes, cylindrically shaped carbon molecules with a diameter of ... of fields, such as biomedical engineering and medical chemistry. ...
... The National Institutes of Health (NIH) has awarded ... University and PATH, a Seattle-based nonprofit organization, to advance ... using patches containing tiny microneedles that dissolve into the ... address key technical issues and advance the microneedle patch ...
... Elsevier ( www.elsevier.com ) , a world-leading ... and services, today announced the launch of SciVerse ... platform that will empower the scientific community to ... search and discovery process through its marketplace and ...
Cached Biology News:Nanotechnology: A dead end for plant cells? 2NIH awards $10 million to advance microneedle patch for flu vaccination 2NIH awards $10 million to advance microneedle patch for flu vaccination 3NIH awards $10 million to advance microneedle patch for flu vaccination 4Elsevier launches SciVerse Applications beta 2Elsevier launches SciVerse Applications beta 3
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
ANTI K. AEROGENES...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
Biology Products: